Management of Peyronie's Disease after Collagenase (Xiaflex:®)

Author(s): Amjad Alwaal, Ahmed Aly Hussein, Uwais B. Zaid and Tom F. Lue

Volume 16, Issue 5, 2015

Page: [484 - 494] Pages: 11

DOI: 10.2174/1389450115666141114163128

Price: $65

Abstract

Although the prevalence of Peyronie’s disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Keywords: Pharmacotherapy, Peyronie’s disease, shock wave therapy, stem cell therapy, collagenase.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy